Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24
March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology/ACC Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia. According to a written statement issued ahead of ACC.24, Bristol Myers Squibb reported that analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF